Novocure Ltd Ord Sh (NVCR)

Jan 13, 2025, 7:00 AM EST - 4 days ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Jan 3, 2025, 7:00 AM EST - 14 days ago

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 9:59 PM EST - 6 weeks ago

NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer

Dec 2, 2024, 1:10 PM EST - 6 weeks ago

Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields

Dec 2, 2024, 10:12 AM EST - 6 weeks ago

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients

Dec 2, 2024, 7:17 AM EST - 6 weeks ago

Novocure's pancreatic cancer treatment meets main goal in late-stage study

Dec 2, 2024, 7:02 AM EST - 6 weeks ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

ZLAB

Dec 2, 2024, 7:00 AM EST - 6 weeks ago

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Nov 27, 2024, 7:00 AM EST - 7 weeks ago

Novocure to Participate in Upcoming Investor Conferences

Nov 21, 2024, 7:05 AM EST - 2 months ago

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Nov 21, 2024, 7:00 AM EST - 2 months ago

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Oct 30, 2024, 11:53 AM EDT - 2 months ago

NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript

Oct 30, 2024, 7:02 AM EDT - 2 months ago

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Oct 30, 2024, 7:00 AM EDT - 2 months ago

Novocure Reports Third Quarter 2024 Financial Results

Oct 16, 2024, 11:00 AM EDT - 3 months ago

NovoCure: There Is Still More Upside

Oct 16, 2024, 7:28 AM EDT - 3 months ago

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients

Oct 15, 2024, 4:43 PM EDT - 3 months ago

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

Oct 1, 2024, 7:00 AM EDT - 3 months ago

Novocure to Report Third Quarter 2024 Financial Results

Sep 9, 2024, 7:00 AM EDT - 4 months ago

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

Sep 3, 2024, 7:00 AM EDT - 4 months ago

Novocure Announces Planned CEO Transition

Aug 28, 2024, 7:00 AM EDT - 5 months ago

Novocure to Participate in 2024 Wells Fargo Healthcare Conference

Aug 14, 2024, 7:00 AM EDT - 5 months ago

Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer

Aug 12, 2024, 5:13 PM EDT - 5 months ago

Biotech stocks: Which drugmakers are worth a buy?

ARGX

Jul 26, 2024, 12:34 PM EDT - 6 months ago

NovoCure Limited: A Post Q2 Analysis

Jul 25, 2024, 12:35 PM EDT - 6 months ago

NovoCure Limited (NVCR) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 7:00 AM EDT - 6 months ago

Novocure Reports Second Quarter 2024 Financial Results

Jul 1, 2024, 7:00 AM EDT - 7 months ago

Novocure to Report Second Quarter 2024 Financial Results

Jun 3, 2024, 8:00 AM EDT - 8 months ago

METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

May 23, 2024, 5:05 PM EDT - 8 months ago

TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany

May 2, 2024, 7:01 AM EDT - 9 months ago

Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon

May 2, 2024, 7:00 AM EDT - 9 months ago

Novocure Reports First Quarter 2024 Financial Results

Apr 24, 2024, 10:45 AM EDT - 9 months ago

Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024

Apr 5, 2024, 7:00 AM EDT - 10 months ago

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

Apr 1, 2024, 7:00 AM EDT - 10 months ago

Novocure to Report First Quarter 2024 Financial Results

Mar 27, 2024, 2:26 PM EDT - 10 months ago

Novocure's stock surges after positive results in brain-cancer trial

Mar 27, 2024, 9:29 AM EDT - 10 months ago

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

ZLAB

Mar 27, 2024, 7:12 AM EDT - 10 months ago

Novocure's lung cancer therapy succeeds in late-stage trial

Mar 27, 2024, 7:00 AM EDT - 10 months ago

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Mar 11, 2024, 7:00 AM EDT - 11 months ago

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

Feb 22, 2024, 10:50 AM EST - 11 months ago

NovoCure Limited (NVCR) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 7:00 AM EST - 11 months ago

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Jan 18, 2024, 7:00 AM EST - 1 year ago

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

Jan 9, 2024, 7:00 AM EST - 1 year ago

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

Jan 8, 2024, 7:00 AM EST - 1 year ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update

Jan 4, 2024, 4:05 PM EST - 1 year ago

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

Dec 27, 2023, 7:00 AM EST - 1 year ago

Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Nov 28, 2023, 7:30 AM EST - 1 year ago

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability

Nov 21, 2023, 7:00 AM EST - 1 year ago

Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference

Nov 16, 2023, 7:54 PM EST - 1 year ago

NovoCure: Significant Upside Even Without A Breakthrough

Nov 10, 2023, 8:00 AM EST - 1 year ago

Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting